High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of a new treatment for multiple
sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal
cord. MS can be progressive and severe and lead to significant disability. The study
treatment involves the use of high-dose chemotherapeutic drugs to suppress the immune system.
The participant's own (autologous) blood-forming (hematopoietic, CD34+) stem cells are
collected before the chemotherapy is given, and then transplanted back into the body
following treatment. Transplantation of autologous hematopoietic stem cells is required to
prevent very prolonged periods of low blood cell counts after the high-dose chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)